MetLife Investment Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-22,695
| Closed | -$504K | – | 2882 |
|
|
2025
Q1 | $504K | Sell |
22,695
-400
| -2% | -$8.88K | ﹤0.01% | 1723 |
|
|
2024
Q4 | $457K | Buy |
23,095
+1,374
| +6% | +$27.2K | ﹤0.01% | 1851 |
|
|
2024
Q3 | $543K | Buy |
21,721
+12,239
| +129% | +$306K | ﹤0.01% | 1740 |
|
|
2024
Q2 | $177K | Sell |
9,482
-7,867
| -45% | -$147K | ﹤0.01% | 2323 |
|
|
2024
Q1 | $342K | Hold |
17,349
| – | – | ﹤0.01% | 1897 |
|
|
2023
Q4 | $304K | Buy |
+17,349
| New | +$304K | ﹤0.01% | 1989 |
|
|
2023
Q3 | – | Sell |
-17,349
| Closed | -$244K | – | 2934 |
|
|
2023
Q2 | $244K | Hold |
17,349
| – | – | ﹤0.01% | 2152 |
|
|
2023
Q1 | $187K | Hold |
17,349
| – | – | ﹤0.01% | 2265 |
|
|
2022
Q4 | $260K | Hold |
17,349
| – | – | ﹤0.01% | 2082 |
|
|
2022
Q3 | $223K | Hold |
17,349
| – | – | ﹤0.01% | 2227 |
|
|
2022
Q2 | $168K | Hold |
17,349
| – | – | ﹤0.01% | 2436 |
|
|
2022
Q1 | $172K | Buy |
17,349
+6,262
| +56% | +$62.2K | ﹤0.01% | 2446 |
|
|
2021
Q4 | $130K | Hold |
11,087
| – | – | ﹤0.01% | 2305 |
|
|
2021
Q3 | $126K | Hold |
11,087
| – | – | ﹤0.01% | 2339 |
|
|
2021
Q2 | $154K | Hold |
11,087
| – | – | ﹤0.01% | 2311 |
|
|
2021
Q1 | $205K | Sell |
11,087
-1,203
| -10% | -$22.3K | ﹤0.01% | 2039 |
|
|
2020
Q4 | $217K | Hold |
12,290
| – | – | ﹤0.01% | 1942 |
|
|
2020
Q3 | $188K | Buy |
12,290
+3,287
| +37% | +$50.4K | ﹤0.01% | 1898 |
|
|
2020
Q2 | $229K | Buy |
9,003
+1,911
| +27% | +$48.7K | ﹤0.01% | 1824 |
|
|
2020
Q1 | $110K | Buy |
+7,092
| New | +$110K | ﹤0.01% | 2019 |
|